Patients taking weight-loss medicines such as Novo Nordisk A/S’s Ozempic and Wegovy are at risk of developing an eye ...

The European Medicines Agency has identified a rare eye condition risk linked to Novo Nordisk’s semaglutide drugs.

Ozempic, which was introduced into the UK in January 2019, having previously been approved in the US in 2017, is an ...

Mr. Funk was the managing editor of Pleroma Media, and worked as a breaking news reporter at The Messenger after spending 25 ...

In the past, studies in type-2 diabetes patients have linked Ozempic to the condition called non-arteritic anterior ischemic ...

US woman Caroline Davis shared incredible before and after images of her weight loss after using semaglutide drug Wegovy.

Semaglutide drugs now include rare vision risk warning as studies link long-term use to optic neuropathy, macular ...

Shares in pharmaceuticals group Novo Nordisk (NVO) remained in good shape today despite reports that its weight loss drugs ...

The European Medicines Agency's safety committee has concluded that the use of Novo Nordisk's popular weight-loss drug Wegovy ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are medicines that help the body lower blood sugar levels. They work ...

The UK's MHRA have issued a warning to people on birth control who may also be taking drugs like Ozempic, Wegovy or Mounjaro ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.